Policies & RegulationsPharmacyHospitalsPharma & DistributionDrug ApprovalsIP IssuesDomestic NDD
  news bulletin  
GSK Korea’s Duac Gel 3% approved for marketing
by Eui Kyoung Yoon (ekyeun@dreamdrug.com)
Published : Sep 23, 2014 09:45:04
GlaxoSmithKline Korea got marketing approval for Duac Gel 3%, its acne treatment, the Ministry of Food and Drug Safety said on September 19.

Duac Gel 3% contains clindamycin 1% and benzoyl peroxide 3%. Its strength is lower than Duac Gel 5% (clindamycin 1.2% and benzoyl peroxide 5%).

Duac Gel 5% currently accounts for 15% of the acne drugs market. The sales of Duac Gel 5% were about 2.3 billion won. Galderma’s Epiduo Gel racked up 2.2 billion won last year.

GSK Korea needs to decide when to roll out Duac Gel 3%. The earliest estimate will be before June, 2015.
 
Reply 0
Name Password
Text
 
Popular News
 
Champix to be covered, starting Feb 2015
First generic version of Omacor approved
OTC drugs will be available at some resorts
Novartis Korea and KPWA agreed on margin increase
MSD’s new COX-2 inhibitor Arcoxia approved
All materials contained on this site are protected by Korean copyright law and may not be reproduced, distributed, transmitted,
displayed, published or broadcast without the prior consent of dailypharm.com